Amber Anderson
Psychiatric/Mental Health · Tell City, INNPI 1326759879
Payments from drug & device makers
Across 167 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$806
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$370
- Axsome Therapeutics, Inc.$223
- Vanda Pharmaceuticals Inc.$212
- Corium, LLC$136
- Otsuka America Pharmaceutical, Inc.$129
- plus $489 from 12 others
What the payments were for
- Food & beverage$2,364100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $806 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $370 |
| Axsome Therapeutics, Inc. | 11 | $223 |
| Vanda Pharmaceuticals Inc. | 11 | $212 |
| Corium, LLC | 11 | $136 |
| Otsuka America Pharmaceutical, Inc. | 6 | $129 |
| Tris Pharma Inc | 7 | $125 |
| Lundbeck LLC | 6 | $115 |
| Novo Nordisk | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Alkermes, Inc. | 2 | $35 |
| Boston Scientific | 1 | $27 |
| Johnson & Johnson | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| GSK | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$2,364 in reported general payments places this provider in the 75th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 60 | $85,544 |
| RexultiBrexpiprazole | 21 | $40,741 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $20,725 |
| TrintellixVortioxetine Hydrobromide | 16 | $8,232 |
| Aripiprazole | 64 | $7,756 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 71 | $5,095 |
| Clomipramine Hcl | 45 | $4,148 |
| Atomoxetine Hcl | 18 | $2,499 |
| Vilazodone Hcl | 19 | $1,745 |
| Ramelteon | 12 | $1,735 |
| Lurasidone Hcl | 19 | $1,432 |
| Amitriptyline Hcl | 54 | $1,131 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 64 | $984 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $640 |
| Clozapine | 24 | $566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $806 | $85,54460 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $129 | $40,74121 claims |
| Alkermes, Inc.Lybalvi | $35 | $20,72513 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $8,23216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Tell City
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.